Revolade approved for treatment of aplastic anaemia

Revolade (eltrombopag) is the first drug to be licensed in the UK for use in patients with acquired severe aplastic anaemia (SAA) who are either refractory to prior immunosuppressive therapy or heavily pretreated and unsuitable for haematopoietic stem cell transplantation (HSCT).

Further information
View Revolade drug record
Summary of Product Characteristics
Manufacturer: Novartis

The current standard of care for SAA includes immunosuppressive therapy or HSCT. Approximately 40% of patients unresponsive to initial immunosuppressive therapy die from infection or bleeding within five years of their diagnosis. 

Revolade is also indicated in chronic immune thrombocytopenic purpura and in thrombocytopenia in patients with hepatitis C.


MIMS Clinics

Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases

Promo Image

Clinical calculators

Handy calculators and conversions for primary care.